Treatment with the nucleotide analogue tenofovir reduces hepatitis B virus (HBV) levels in patients coinfected with HIV, and appears to be equally effective in patients who have and have not been exposed to lamivudine.
The findings are published in the January 3rd issue of AIDS. As the authors point out, lamivudine is known to be an effective anti-HBV agent in coinfected patients. However, lamivudine-resistant HBV develops in at least 50% of patients who have been treated for 2 years or longer, so there is a definite need for other anti-HBV agents in this population.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!